Suicidal ideation and attempts in brain tumor patients and survivors: A systematic review

Abstract

Background Subsequent to a diagnosis of a brain tumor, psychological distress has been associated with negative effects on mental health as well as suicidality. The magnitude of such impact has been understudied in the literature. We conducted a systematic review to examine the impact of a brain tumor on suicidality (both ideation and attempts). Methods In accordance with the PRISMA guidelines, we searched for relevant peer-reviewed journal articles on PubMed, Scopus, and Web of Science databases from inception to October 20th, 2022. Studies investigating suicide ideation and/or attempt among patients with brain tumors were included. Results Our search yielded 1,998 articles which were screened for eligibility. Seven studies consisting of 204,260 patients were included in the final review. Four studies comprising 203,906 patients (99.8%) reported elevated suicidal ideation and suicide attempt incidence compared with the general population. Prevalence of ideation and attempts ranged from 6.0% to 21.5% and 0.03% to 3.33%, respectively. Anxiety, depression, pain severity, physical impairment, glioblastoma diagnosis, male sex, and older age emerged as the primary risk factors associated with increased risk of suicidal ideation and attempts. Conclusion Suicidal ideation and attempts are increased in patients and survivors of brain tumors compared to the general population. Early identification of patients exhibiting these behaviors is crucial for providing timely psychiatric support in neuro-oncological settings to mitigate potential harm. Future research is required to understand pharmacological, neurobiological, and psychiatric mechanisms that predispose brain tumor patients to suicidality.

The Role of Ketone Bodies in Treatment Individualization of Glioblastoma Patients

“…However, the average survival duration is still less than 15 months, and the 5-year survival is below 10% [ 6 , 8 , 10 , 11 ]. These patients also have an increased risk of suicide, possibly due to the poor prognosis of this pathology and because of treatment-related side effects, such as mood-altering steroids [ 53 ]. Establishing new treatment regimens based on different peripheral markers that are easy to determine from the patient’s peripheral blood, such as KBs, and introducing adjuvant therapies based on these parameters, such as ketogenic diets, and thus essentially individualizing treatments, may result in an increase in the survival rate.…”

Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings

“…Molecular targeted therapies have emerged as a promising avenue for addressing GBM's complexity and limited treatment options [6][7][8][9][10][11]. Frequent genetic alterations, such as p53 mutations, EGFR amplification, CDKN2a deletion, and PTEN mutations, offer potential therapeutic targets [11][12][13][14][15][16][17][18][19][20][21]. Current treatments, including surgery, radiation, and chemotherapy, yield a median survival of only 15 months for GBM patients, with frequent aggressive recurrences [12].…”

“…Current treatments, including surgery, radiation, and chemotherapy, yield a median survival of only 15 months for GBM patients, with frequent aggressive recurrences [12]. Patients also contend with significant psychological challenges that impact their quality of life [14].…”

Extracellular vesicles in the breast cancer brain metastasis: physiological functions and clinical applications

“…Furthermore, the unique property of the brain, protected by the blood-brain barrier (BBB), limits the availability of safe and effective treatment options. The poor prognosis of brain metastasis patients, characterized by high mortality rate and the difficulty of treatment, is speculated to be a significant factor contributing to increased psychological burden on patients and potentially leading to suicidal ideation ( Mofatteh et al, 2023 ). For breast cancer to metastasize to distant tissues such as the brain, circulating tumor cells (CTCs) need to be released from the primary tumor site and adhere to the metastatic site ( Bidard et al, 2016 ; Boral et al, 2017 ).…”